News
Intervention for AVM still too high risk: The latest from ARUBA
- Author:
- Sue Hughes
The ARUBA trial was stopped prematurely because of a much higher rate of death and stroke in the intervention group.
News
Circadian rhythm changes linked to future Parkinson’s disease risk
- Author:
- Sue Hughes
Circadian rhythmicity could be a promising intervention target and may open new opportunities for the prevention and management of Parkinson’s...
News
CVD risk continues to fall down to systolic BP of 90 mm HG
- Author:
- Sue Hughes
“From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”
News
Relapsing, progressive MS classifications should be abandoned
- Author:
- Sue Hughes
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”
News
COVID-19 neurologic effects: Does the virus directly attack the brain?
- Author:
- Sue Hughes
There are neurologic sequelae of COVID-19. “We need to be alert to these, and to try to understand the potential long-term consequences.”
News
No benefit of three commonly used medications for MS fatigue
- Author:
- Sue Hughes
These findings will hopefully encourage doctors to “think twice before prescribing these medications that could be harmful and have no clear...
News
More from REDUCE-IT: Icosapent ethyl cuts revascularization by a third
- Author:
- Sue Hughes
The high-strength eicosapentaenoic acid product reduced revascularizations by one-third in patients at increased cardiovascular risk and...
News
ACE inhibitors and severe COVID-19: Protective in older patients?
- Author:
- Sue Hughes
A randomized trial is planned after a study showed that fewer older hypertensive patients taking ACE inhibitors were hospitalized with COVID-19....
News
Statins and ICH: new meta-analysis
- Author:
- Sue Hughes
The risk for cerebral ischemia was significantly lower in those who received statins compared with who did not.
News
New angiotensin studies in COVID-19 give more reassurance
- Author:
- Sue Hughes
A deluge of new data does not suggest harm with ACE inhibitors and angiotensin blockers in COVID-19 rates or outcomes.
News
Diastolic dysfunction is a common risk factor for cognitive decline
- Author:
- Sue Hughes
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic...
News
Remdesivir now ‘standard of care’ for COVID-19, Fauci says
- Author:
- Sue Hughes
The interim results show that time to recovery was 31% faster for patients who received remdesivir than for those who received placebo.
News
Angiotensin drugs and COVID-19: More reassuring data
- Author:
- Sue Hughes
Data from one Wuhan hospital show no difference in COVID-19 severity or mortality in patients with hypertension...
News
Sodium nitrite disappoints in cardiac arrest
- Author:
- Sue Hughes
The drug did not significantly improve patients’ chances of being admitted to or discharged from the hospital...
Article
Second trial supports ticagrelor alone in ACS after PCI: TICO
- Author:
- Sue Hughes
The TICO trial confirms results seen in TWILIGHT showing benefits of stopping aspirin 3 months after stenting.